CDMO Industry : India's Medicine Growth Story
The Biosecure Act isn’t just another policy update – it could reshape the global CDMO landscape.
For decades, China dominated pharma outsourcing.
Today, geopolitical risk and supply chain diversification are pushing global innovators to look beyond a single manufacturing hub.
And India is already part of that shift way ahead of others.
• Approx. 45% of US generics supplied by India.
• India has the most USFDA-approved plants outside the US.
• A $195.3B bioeconomy, growing at a 17.8% CAGR since 2020 – independent of any US policy.
Swipe through to understand why this isn’t just about the Bio secure Act – it’s one of the biggest structural shifts shaping the future of global pharma.
To READ in detail click here.
AIF Investor Charter 
NIVESHAAY INVESTMENT ADVISORS
508, SNS Platina, Near Someshwara Enclave, Vesu, Surat, Gujarat-395007
(+91) 7859870559
research.smallcase@niveshaay.com (Equity Baskets)
NIVESHAAY INVESTMENT MANAGEMENT PRIVATE LIMITED
610, SNS Platina, Near Someshwara Enclave, Vesu, Surat, Gujarat-395007
(+91) 7836915478
contactaif@niveshaay.com (AIF)
SEBI Registration No. : INH000017338, IN/AIF3/24-25/1571, IN/AIF2/24-25/1607, INP000009506 | BASL Membership ID: 6276
Disclaimer:
Investment in Securities Market are subject to market risks. Read all related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
The securities quoted are for illustration only and are not recommendatory
NIVESHAAY INVESTMENT ADVISORS © . All Rights Reserved., NIVESHAAY INVESTMENT MANAGEMENT PRIVATE LIMITED © . All Rights Reserved.Smart ODR